Amanda J. Parker

Congress’s delay of new federal hemp restrictions protects near-term patient access and gives lawmakers more time to pursue a comprehensive policy that supports safety, clinical oversight and responsible state regulation.

AACPN is calling for expanded scientific research into psychedelic-assisted therapies as potential trauma treatment options for survivors of sexual violence. The organization says survivors deserve compassionate, evidence-based care and continued research into emerging mental health therapies including MDMA, psilocybin, and ketamine-assisted treatment.

AACPN welcomes the U.S. Department of Veterans Affairs’ launch of a clinical trial evaluating MDMA-assisted therapy for veterans living with PTSD and alcohol use disorder. The organization says rigorous scientific research is essential to understanding whether emerging therapies can safely and effectively support veterans and other trauma survivors facing complex behavioral health challenges.